Therefore, it is our conviction based on the recent developments that interventions interfering with the hyperactivation of the RAS-RAF-MEK-ERK pathway still carry great potential in the treatment of associated tumor entities, giving cause for new hope in affected patients. This evidence concerns the gene MAP2K7 and neoplasm.